These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 25340580)
1. Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytotoxic gold(III) compound Auoxo3. Russo Krauss I; Messori L; Cinellu MA; Marasco D; Sirignano R; Merlino A Dalton Trans; 2014 Dec; 43(46):17483-8. PubMed ID: 25340580 [TBL] [Abstract][Full Text] [Related]
2. Protein-mediated disproportionation of Au(i): insights from the structures of adducts of Au(iii) compounds bearing N,N-pyridylbenzimidazole derivatives with lysozyme. Ferraro G; Giorgio A; Mansour AM; Merlino A Dalton Trans; 2019 Oct; 48(37):14027-14035. PubMed ID: 31490509 [TBL] [Abstract][Full Text] [Related]
3. Gold-based drug encapsulation within a ferritin nanocage: X-ray structure and biological evaluation as a potential anticancer agent of the Auoxo3-loaded protein. Ferraro G; Monti DM; Amoresano A; Pontillo N; Petruk G; Pane F; Cinellu MA; Merlino A Chem Commun (Camb); 2016 Jul; 52(61):9518-21. PubMed ID: 27326513 [TBL] [Abstract][Full Text] [Related]
4. Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme. Ferraro G; Massai L; Messori L; Cinellu MA; Merlino A Biometals; 2015 Aug; 28(4):745-54. PubMed ID: 26054833 [TBL] [Abstract][Full Text] [Related]
5. The mode of action of anticancer gold-based drugs: a structural perspective. Messori L; Scaletti F; Massai L; Cinellu MA; Gabbiani C; Vergara A; Merlino A Chem Commun (Camb); 2013 Oct; 49(86):10100-2. PubMed ID: 24045294 [TBL] [Abstract][Full Text] [Related]
6. Mechanistic studies on two dinuclear organogold(III) compounds showing appreciable antiproliferative properties and a high redox stability. Gabbiani C; Casini A; Kelter G; Cocco F; Cinellu MA; Fiebig HH; Messori L Metallomics; 2011 Dec; 3(12):1318-23. PubMed ID: 21887452 [TBL] [Abstract][Full Text] [Related]
7. The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme. Messori L; Marzo T; Merlino A Chem Commun (Camb); 2014 Aug; 50(61):8360-2. PubMed ID: 24943911 [TBL] [Abstract][Full Text] [Related]
8. Peculiar features in the crystal structure of the adduct formed between cis-PtI2(NH3)2 and hen egg white lysozyme. Messori L; Marzo T; Gabbiani C; Valdes AA; Quiroga AG; Merlino A Inorg Chem; 2013 Dec; 52(24):13827-9. PubMed ID: 24256441 [TBL] [Abstract][Full Text] [Related]
9. Structural and solution chemistry, protein binding and antiproliferative profiles of gold(I)/(III) complexes bearing the saccharinato ligand. Maiore L; Cinellu MA; Michelucci E; Moneti G; Nobili S; Landini I; Mini E; Guerri A; Gabbiani C; Messori L J Inorg Biochem; 2011 Mar; 105(3):348-55. PubMed ID: 21421122 [TBL] [Abstract][Full Text] [Related]
10. Synthesis, structural characterization, and theoretical studies of gold(I) and gold(I)-gold(III) thiolate complexes: quenching of gold(I) thiolate luminescence. Bardají M; Calhorda MJ; Costa PJ; Jones PG; Laguna A; Reyes Pérez M; Villacampa MD Inorg Chem; 2006 Feb; 45(3):1059-68. PubMed ID: 16441114 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, structural characterization, solution behavior, and in vitro antiproliferative properties of a series of gold complexes with 2-(2'-pyridyl)benzimidazole as ligand: comparisons of gold(III) versus gold(I) and mononuclear versus binuclear derivatives. Serratrice M; Cinellu MA; Maiore L; Pilo M; Zucca A; Gabbiani C; Guerri A; Landini I; Nobili S; Mini E; Messori L Inorg Chem; 2012 Mar; 51(5):3161-71. PubMed ID: 22339487 [TBL] [Abstract][Full Text] [Related]
12. Stable anticancer gold(III)-porphyrin complexes: effects of porphyrin structure. Sun RW; Li CK; Ma DL; Yan JJ; Lok CN; Leung CH; Zhu N; Che CM Chemistry; 2010 Mar; 16(10):3097-113. PubMed ID: 20162647 [TBL] [Abstract][Full Text] [Related]
13. Effect of temperature on the interaction of cisplatin with the model protein hen egg white lysozyme. Ferraro G; Pica A; Russo Krauss I; Pane F; Amoresano A; Merlino A J Biol Inorg Chem; 2016 Jul; 21(4):433-42. PubMed ID: 27040953 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, characterisation and biological properties of gold(III) compounds with modified bipyridine and bipyridylamine ligands. Casini A; Diawara MC; Scopelliti R; Zakeeruddin SM; Grätzel M; Dyson PJ Dalton Trans; 2010 Mar; 39(9):2239-45. PubMed ID: 20162197 [TBL] [Abstract][Full Text] [Related]
15. Photophysical properties and electropolymerization of gold complexes of 3,3''-diethynyl-2,2':5',2''-terthiophene. Kuchison AM; Wolf MO; Patrick BO Inorg Chem; 2010 Oct; 49(19):8802-12. PubMed ID: 20809610 [TBL] [Abstract][Full Text] [Related]
16. Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles. Massai L; Cirri D; Michelucci E; Bartoli G; Guerri A; Cinellu MA; Cocco F; Gabbiani C; Messori L Biometals; 2016 Oct; 29(5):863-72. PubMed ID: 27476157 [TBL] [Abstract][Full Text] [Related]
17. Interactions of gold-based drugs with proteins: crystal structure of the adduct formed between ribonuclease A and a cytotoxic gold(III) compound. Messori L; Scaletti F; Massai L; Cinellu MA; Russo Krauss I; di Martino G; Vergara A; Paduano L; Merlino A Metallomics; 2014 Feb; 6(2):233-6. PubMed ID: 24287583 [TBL] [Abstract][Full Text] [Related]
18. Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors. Wilson CR; Fagenson AM; Ruangpradit W; Muller MT; Munro OQ Inorg Chem; 2013 Jul; 52(14):7889-906. PubMed ID: 23815163 [TBL] [Abstract][Full Text] [Related]
19. Synthesis, structural characterisation and anti-proliferative activity of NHC gold amino acid and peptide conjugates. Lemke J; Pinto A; Niehoff P; Vasylyeva V; Metzler-Nolte N Dalton Trans; 2009 Sep; (35):7063-70. PubMed ID: 20449149 [TBL] [Abstract][Full Text] [Related]